Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finch Therapeutics Group Inc.

http://finchtherapeutics.com/

Latest From Finch Therapeutics Group Inc.

Ferring's Microbiome Success Based On Much More Than Gut Instinct

"There's a lot of hope and hype still in the microbiome sphere," Ferring's president Per Falk tells Scrip, but the rewards could be considerable for companies that can deliver well-documented safety and efficacy data and do not take try to take shortcuts.

Leadership Infectious Diseases

Venture Funding Deals: Korean D&D Raises $137.1m For Subsidiary Model

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in July and August.

Deals Financing

Finance Watch: Chinook Debuts With $65m For Precision Kidney Disease Medicines

Private Company Edition: The start-up intends to take multiple drug candidates into the clinic by 2021. Also, Graybug Vision raises an $80m series B and Finch closes a $53m series C.

Financing Business Strategies

Microbiome Offers Rich Pickings As Takeda Becomes Enterome's Second Big Pharma Crohn's Partner

Takeda's $50m+ deal for Enterome's EB8018 is based on a separate platform from that being used under the French company's collaboration with Johnson & Johnson.

Inflammation Gastrointestinal
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Alias(es)
  • Finch Therapeutics Inc.
  • NextBiome Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Finch Therapeutics Group Inc.
  • Senior Management
  • Mark Smith, PhD, CEO
    Gregory Perry, CFO
    Ulrich Thienel, MD, PhD, CMO
  • Contact Info
  • Finch Therapeutics Group Inc.
    Phone: (617) 229-6499
    200 Inner Belt Rd., Ste. 400
    Somerville, MA 02143
    USA
UsernamePublicRestriction

Register